Alnylam Pharmaceuticals vs Arrakis Therapeutics

Alnylam Pharmaceuticals vs Arrakis Therapeutics, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Alnylam Pharmaceuticals is on 19/100 and Arrakis Therapeutics on 46/100.

Alnylam Pharmaceuticals logo
Alnylam PharmaceuticalsBiopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat rare and prevalent genetic diseases.
Try Alnylam Pharmaceuticals
Arrakis Therapeutics logo
Arrakis TherapeuticsArrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Mas
Try Arrakis Therapeutics

Where each one leads

Alnylam Pharmaceuticals

  • agent readiness: 42/100 against 37/100
  • domain rating: 72/100 against 29/100

Arrakis Therapeutics

  • our overall score: 46/100 against 19/100

At a glance

MeasureAlnylam PharmaceuticalsArrakis Therapeutics
What it isBiopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat rare and prevalent genetic diseases.Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Mas
CategoryBiotechnology, Pharmaceuticals, HealthcareBiotech, Drug Discovery, RNA Therapeutics, Small Molecule Drugs
Sells toBusiness modelB2BB2B
OfferingServicesSoftware
Founded20022014
HeadquartersCambridge, United StatesWaltham, United States
StatusActiveActive

Size, funding and growth

MeasureAlnylam PharmaceuticalsArrakis Therapeutics
EmployeesNot published52
LinkedIn followersNot published12,956

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureAlnylam PharmaceuticalsArrakis Therapeutics
StartupHub scoreOur 0-100 rating19/10046/100
TractionNot published17/100
Team70/100Not published
Search visibility11/10034/100
QualityNot published68/100
Agent readinessHow well an AI agent can read and act on the siteD (42/100)F (37/100)
Domain ratingLink authority, 0-10072/10029/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureAlnylam PharmaceuticalsArrakis Therapeutics
HostingSelf ManagedNot detected
CDNNot detectedCloudflare
CMSNot detectedWordPress
FrameworksJquery, BootstrapJquery
AnalyticsNot detectedGoogle Analytics 4
Open sourceYesNo

What users say

MeasureAlnylam PharmaceuticalsArrakis Therapeutics
Reddit sentimentThreads we trackNot published2 positive, 2 negative across 4 threads
Arrakis Therapeutics
Pharmaunternehmen - Roche schliesst Lizenzvereinbarung mit Arrakis Therapeutics, Der Pharmakonzern Roche hat sich auf eine Lizenzvereinbarung mit dem US-Biotechunternehmen Arrakis Therapeutics geeinigt..
r/chpresseschau

Alnylam Pharmaceuticals vs Arrakis Therapeutics: common questions

Which is better, Alnylam Pharmaceuticals or Arrakis Therapeutics?

On our 0-100 score Arrakis Therapeutics rates higher (46/100 against 19/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.

How do Alnylam Pharmaceuticals and Arrakis Therapeutics compare on the numbers?

Alnylam Pharmaceuticals leads on agent readiness (42/100 against 37/100), domain rating (72/100 against 29/100). Arrakis Therapeutics leads on our overall score (46/100 against 19/100).

What do real users say about Alnylam Pharmaceuticals and Arrakis Therapeutics?

Arrakis Therapeutics: 2 positive and 2 negative mentions across 4 Reddit threads we track, mostly in r/chpresseschau.

Read the full Alnylam Pharmaceuticals review and pricing or the Arrakis Therapeutics review and pricing. You can also browse other Alnylam Pharmaceuticals alternatives we track.